SCHEMBL5014847

SCHEMBL5014847

O=C(S)N1CCC(c2nc3ccccc3o2)CC1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.73
HTR2B P41595 1/20 0.67
THRB P10828 2/20 0.63
USP2 O75604 1/20 0.63
TP53 P04637 2/20 0.60
EPHX1 P07099 1/20 0.60
EPHX2 P34913 1/20 0.60
KCNH2 Q12809 1/20 0.60
CACNA1C Q13936 1/20 0.60
SCN5A Q14524 1/20 0.60
MAPT P10636 2/20 0.59
ALDH1A1 P00352 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
POLB P06746 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31562922 0.83 LMNA (0.68) LMNAHTR2BTHRBUSP2TP53
SCHEMBL5014849 0.82 LMNA (0.70) LMNAHTR2BTHRBUSP2TP53
SCHEMBL26862272 0.79 LMNA (0.60) LMNAHTR2BTHRBUSP2TP53
SCHEMBL13810503 0.79 LMNA (0.61) LMNAHTR2BTHRBUSP2TP53
SCHEMBL21361595 0.79 LMNA (0.61) LMNAHTR2BTHRBUSP2TP53
SCHEMBL14834014 0.78 LMNA (0.60) LMNAHTR2BTHRBUSP2TP53
SCHEMBL17689220 0.76 LMNA (0.64) LMNAHTR2BTHRBUSP2TP53
SCHEMBL4457699 0.76 RAB9A (0.59) LMNAHTR2BTHRBUSP2TP53
SCHEMBL14895871 0.76 LMNA (0.57) LMNAHTR2BTHRBUSP2TP53
SCHEMBL12466798 0.75 USP2 (0.61) LMNAHTR2BTHRBUSP2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9539261-B2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration NEURONASCENT, INC. (US) 2017-01-10 US disclosed
US-20150209371-A1 Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. 2015-07-30 US disclosed
US-8999972-B2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration NEURONASCENT, INC. (US) 2015-04-07 US disclosed
US-20110319391-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION NEURONASCENT, INC. 2011-12-29 US disclosed
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. (US) 2008-09-25 US disclosed
EP-1937252-A2 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION Neuronascent, Inc. (US) 2008-07-02 EP disclosed
WO-2007035722-A2 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION NEURONASCENT, INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319391-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION DCX, BDNF, GAP43 LMNA 1661/4885HTR2B 1397/4885THRB 2439/4885
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 LMNA 991/4885HTR2B 1218/4885THRB 1103/4885
US-20150209371-A1 Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 LMNA 1661/4885HTR2B 1397/4885THRB 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.